Gatehouse Bio
  • Technology
  • Biology
  • Pipeline
  • News & Publications
  • Our Team
  • Contact Us
Menu
  • Technology
  • Biology
  • Pipeline
  • News & Publications
  • Our Team
  • Contact Us

Category: Press Releases

Gatehouse Bio Extends Its Partnership with AstraZeneca to Develop RNA Therapeutics for Heart Failure

BOSTON–(BUSINESS WIRE)–Gatehouse Bio, a pioneer in small RNA therapeutics, and AstraZeneca, a global, science-led biopharmaceutical company, are advancing their partnership, to create RNA therapeutics for the treatment of heart failure with preserved ejection fraction (HFpEF).

Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery

Collaboration will use Gatehouse Bio’s AI-Powered Analytics Platform to identify potential drug targets in respiratory and cardiovascular diseases

Gatehouse Bio Receives FDA Support for AI-Powered Pathway Analytics Platform

Platform uncovers biomarkers that track progression of Huntington’s disease 20 years before symptomatic onset

Gatehouse Bio to Accelerate its Biomarker Discovery Platform and Services at IndieBio

… early-stage biotech startup based in Boston who has developed a software platform technology to identify small RNA biomarkers, announced today it will participate in the IndieBio Accelerator Program in San Francisco, CA.

Contact Us

All rights reserved. 

22 Strathmore Rd. Suite 411, Natick, MA 01760            

Thanks for your interest! Please fill out the form below to download a copy of our case study

David Salzman, PhD

As founder and CEO of Gatehouse Bio, David has over 14 years of research expertise and experience in microRNA and sRNA biology. He is the force behind the science and technological development required for identifying sRNA diagnostics, targeted assay design, validation, and subsequent product development. He was previously a postdoctoral fellow at the Yale School of Medicine and a scientist at Biogen, where he gained experience in developing clinical and preclinincal biomarker, PK/PD, and diagnostic platforms. David also served as the CSO of MiraDx, spearheading projects to commercialize germline DNA biomarkers in oncology. He earned his PhD in Molecular Biology and Biochemistry from the University of Connecticut and a BS in Environmental Science from the University of Hartford.


View his publication record here.

If you have any questions or would like to set up a call to talk about a future partnership, we would love to hear from you. Please fill out the form below and one of our members will be in touch.